Expression of SDF‑1 and CXCR4 transcript variants and CXCR7 in epithelial ovarian cancer

Jaszczynska‑Nowinka,Karolina; Rucinski,Marcin; Ziolkowska,Agnieszka; Markowska,Anna; Malendowicz,Ludwik  K.

doi:10.3892/ol.2014.1897

Expression of SDF‑1 and CXCR4 transcript variants and CXCR7 in epithelial ovarian cancer

Authors:
- Karolina Jaszczynska‑Nowinka
- Marcin Rucinski
- Agnieszka Ziolkowska
- Anna Markowska
- Ludwik K. Malendowicz
View Affiliations

Affiliations: Department of Oncology, Poznań University of Medical Sciences, Poznań 60‑781, Poland, Department of Histology and Embryology, Poznań University of Medical Sciences, Poznań 60‑781, Poland, Department of Perinatology and Gynecology, Poznań University of Medical Sciences, Poznań 60‑781, Poland
Published online on: February 20, 2014 https://doi.org/10.3892/ol.2014.1897
Pages: 1618-1624

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemokine stromal cell‑derived factor‑1 (SDF‑1) and its receptors, CXCR4 and CXCR7, have been implicated in epithelial ovarian cancer progression and metastasis. However, limited data are available on the expression levels of SDF‑1 and CXCR4 variants and CXCR7 in human epithelial ovarian cancer. The present study aimed to characterize the expression pattern and levels of SDF‑1, CXCR4 and CXCR7 in normal human ovaries and epithelial ovarian cancer. The expression of SDF‑1 and CXCR4 transcript variants and CXCR7 was determined by quantitative polymerase chain reaction (qPCR). Plasma SDF‑1α levels were determined by commercially available EIA kits and cancer antigen 125 (CA 125) levels were quantified by automated microparticle enzyme immunosorbent assay. High expression levels of SDF‑1 transcript variant 1 were identified in ovarian cancer and control ovaries. By contrast, in both groups the expression levels of SDF‑1 transcript variants 3 and 4 were extremely low. Furthermore, SDF‑1 variant 1 levels were notably higher in epithelial ovarian cancer than in control ovaries, while data for the remaining transcripts were similar in both groups. CXCR4 transcript variant 2 and CXCR7 expression levels in normal and neoplastic ovaries were similar. In both groups, CXCR4 transcript variant 2 was not detected. Plasma SDF‑1α levels were notably higher in females with epithelial ovarian cancer than in the control ovaries. Elevated levels of blood SDF‑1α were found prior to surgery, 6 days after surgery and following completion of the first chemotherapy course. These increases were independent of the type of epithelial ovarian cancer. Our results suggest that the expression of SDF‑1 and the genes controlling alternative splicing are elevated in epithelial ovarian cancer, leading to an increased formation of SDF‑1 variant 1. Elevated plasma SDF‑1α levels in epithelial ovarian cancer patients are not associated with the presence of tumors and/or metastases, however reflect a general response to the disease.

View Figures

View References

1	Tashiro K, Tada H, Heilker R, et al: Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science. 261:600–603. 1993. View Article : Google Scholar : PubMed/NCBI
2	Murphy PM, Baggiolini M, Charo IF, et al: International union of pharmacology. XXII Nomenclature for chemokine receptors. Pharmacol Rev. 52:145–176. 2000.PubMed/NCBI
3	Balabanian K, Lagane B, Infantino S, et al: The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem. 280:35760–35766. 2005. View Article : Google Scholar
4	Ratajczak MZ, Zuba-Surma E, Kucia M, et al: The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia. 20:1915–1924. 2006. View Article : Google Scholar : PubMed/NCBI
5	Burns JM, Summers BC, Wang Y, et al: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 203:2201–2213. 2006. View Article : Google Scholar : PubMed/NCBI
6	Kryczek I, Wei S, Keller E, Liu R and Zou W: Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol. 292:C987–C995. 2007. View Article : Google Scholar : PubMed/NCBI
7	Scotton CJ, Wilson JL, Milliken D, Stamp G and Balkwill FR: Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. 61:4961–4965. 2001.PubMed/NCBI
8	Scotton CJ, Wilson JL, Scott K, et al: Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62:5930–5938. 2002.PubMed/NCBI
9	Feuerer M, Beckhove P, Bai L, et al: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med. 7:452–458. 2001. View Article : Google Scholar : PubMed/NCBI
10	Zou W, Machelon V, Coulomb-L’Hermin A, et al: Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 7:1339–1346. 2001. View Article : Google Scholar : PubMed/NCBI
11	Kryczek I, Gryboś M, Dlubek D, Klimczak A, Rabczyński J and Lange A: Accumulation of CD45RO(+) cells in peritoneal carcinomatous fluid favours survival of ovarian carcinoma patients. Cancer Immunol Immunother. 51:513–519. 2002.
12	Jaszczyñska-Nowinka K and Markowska A: New cytokine: stromal derived factor-1. Eur J Gynaecol Oncol. 30:124–127. 2009.PubMed/NCBI
13	Broxmeyer HE, Orschell CM, Clapp DW, et al: Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 201:1307–1318. 2005. View Article : Google Scholar
14	Zhang T, Somasundaram R, Berencsi K, et al: CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol. 174:5856–5863. 2005. View Article : Google Scholar
15	Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
16	Jiang YP, Wu XH, Shi B, Wu WX and Yin GR: Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol. 103:226–233. 2006. View Article : Google Scholar
17	Furuya M, Suyama T, Usui H, et al: Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol. 38:1676–1687. 2007. View Article : Google Scholar : PubMed/NCBI
18	Pils D, Pinter A, Reibenwein J, et al: In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. Br J Cancer. 96:485–491. 2007. View Article : Google Scholar : PubMed/NCBI
19	Rucinski M, Andreis PG, Ziolkowska A, Nussdorfer GG and Malendowicz LK: Differential expression and function of beacon in the rat adrenal cortex and medulla. Int J Mol Med. 16:35–40. 2005.PubMed/NCBI
20	Rucinski M, Zok A, Guidolin D, De Caro R and Malendowicz LK: Expression of precerebellins in cultured rat calvaria osteoblast-like cells. Int J Mol Med. 22:553–558. 2008.
21	Rucinski M, Ziolkowska A, Tyczewska M and Malendowicz LK: Expression of prepro-ghrelin and related receptor genes in the rat adrenal gland and evidences that ghrelin exerts a potent stimulating effect on corticosterone secretion by cultured rat adrenocortical cells. Peptides. 30:1448–1455. 2009. View Article : Google Scholar
22	Gleichmann M, Gillen C, Czardybon M, et al: Cloning and characterization of SDF-1gamma, a novel SDF-1 chemokine transcript with developmentally regulated expression in the nervous system. Eur J Neurosci. 12:1857–1866. 2000. View Article : Google Scholar
23	De La Luz Sierra M, Yang F, Narazaki M, et al: Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood. 103:2452–2459. 2004.PubMed/NCBI
24	Yu L, Cecil J, Peng SB, Schrementi J, et al: Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene. 374:174–179. 2006. View Article : Google Scholar : PubMed/NCBI
25	Janowski M: Functional diversity of SDF-1 splicing variants. Cell Adh Migr. 3:243–249. 2009. View Article : Google Scholar : PubMed/NCBI
26	Nowak-Markwitz E, Puła B, Szajnik M, Dziegiel P, Piotrowska A, Zabel M and Spaczyński M: Expression of survivin, SDF-1 and CXCR4 on tumor cells in ovarian cancer. Ginekol Pol. 81:674–677. 2010.(In Polish).
27	Davis DA, Singer KE, De La Luz Sierra M, et al: Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. Blood. 105:4561–4568. 2005. View Article : Google Scholar : PubMed/NCBI
28	Kryczek I, Lange A, Mottram P, et al: CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65:465–472. 2005.
29	Oberlin E, Amara A, Bachelerie F, et al: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 382:833–835. 1996. View Article : Google Scholar : PubMed/NCBI
30	Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J and Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 382:829–833. 1996. View Article : Google Scholar : PubMed/NCBI
31	D’Apuzzo M, Rolink A, Loetscher M, et al: The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol. 27:1788–1793. 1997.PubMed/NCBI
32	Fulton AM: The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep. 11:125–131. 2009. View Article : Google Scholar : PubMed/NCBI
33	Kucia M, Reca R, Miekus K, et al: Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 23:879–894. 2005. View Article : Google Scholar
34	Sun X, Cheng G, Hao M, et al: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
35	Wang J, Cai J, Han F, et al: Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway. Int J Gynecol Cancer. 21:981–987. 2011. View Article : Google Scholar
36	Maksym RB, Tarnowski M, Grymula K, et al: The role of stromal-derived factor-1 - CXCR7 axis in development and cancer. Eur J Pharmacol. 625:31–40. 2009. View Article : Google Scholar : PubMed/NCBI
37	Potter SM, Dwyer RM, Curran CE, Hennessy E, Harrington KA, Griffin DG and Kerin MJ: Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones. Breast Cancer Res Treat. 115:279–287. 2009. View Article : Google Scholar
38	Tsai HT, Tee YT, Hsieh YH, et al: Elevated plasma stromal cell-derived factor 1 protein and its gene polymorphism in patients with pelvic inflammatory disease. Reprod Sci. 16:610–617. 2009. View Article : Google Scholar : PubMed/NCBI
39	Hansen IB, Ellingsen T, Hornung N, Poulsen JH, Lottenburger T and Stengaard-Pedersen K: Plasma level of CXC-chemokine CXCL12 is increased in rheumatoid arthritis and is independent of disease activity and methotrexate treatment. J Rheumatol. 33:1754–1759. 2006.
40	Kim HK, Kim JE, Chung J, Lee DS, Han KS, Park S and Cho HI: Plasma level of stromal derived factor-1 (SDF-1) is increased in disseminated intravascular coagulation patients who have poor outcomes: in vitro effect of SDF-1 on coagulopathy. Thromb Res. 120:559–566. 2007. View Article : Google Scholar
41	Robak E, Kulczycka L, Sysa-Jedrzejowska A, Wierzbowska A and Robak T: Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw. 18:181–187. 2007.
42	Huang R, Lin Y, Flowers L, et al: Molecular profiling of circulating cytokine levels in human ovarian cancer patients. Cancer Genomics Proteomics. 1:23–32. 2004.
43	Popple A, Durrant LG, Spendlove I, Rolland P, Scott IV, Deen S and Ramage JM: The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. Br J Cancer. 106:1306–1313. 2012. View Article : Google Scholar : PubMed/NCBI
44	Machelon V, Gaudin F, Camilleri-Broët S, et al: CXCL12 expression by healthy and malignant ovarian epithelial cells. BMC Cancer. 11:972011. View Article : Google Scholar : PubMed/NCBI